ReviewCNS spectrums2025
From betel nuts to Cobenfy: how an ancient recreational drug gave rise to a new class of schizophrenia medications.
Review in CNS spectrums, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From schizophrenia to dementia: Is Cobenfy a potential treatment for behavioral and psychological symptoms of dementia?The Journal of international medical research · 2026Article
- From Betel Nuts to Cobenfy: How an Ancient Recreational Drug Gave Rise to a New Class of Schizophrenia Medications - ERRATUM.CNS spectrums · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
The term "betel" most accurately refers to the betel pepper (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.